JohnMichaelRobinsonDOFACOG, FACOOG, FACS

Obstetrics & Gynecology • Wilmington, NC

Gynecologic Oncology

Physician

Join to view full profile

Dr. Robinson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Robinson's full profile

Already have an account?

Office
2131 S 17th St
Wilmington, NC 28401
Phone+1 910-667-3000

Fax+1 910-815-5464

Education & Training

Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Gynecologic Oncology, 2015 - 2018
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Obstetrics and Gynecology, 2010 - 2014
University of New England College of Osteopathic MedicineClass of 2010

Certifications & Licensure

NC State License 2018 - 2025
NJ State License 2011 - 2021
AOA Board of Obstetrics and Gynecology Gynecologic Oncology (CAQ)
AOA Board of Obstetrics and Gynecology Obstetrics & Gynecology

Clinical Trials

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Start of enrollment: 2022 Nov 16
Recruiting
Phase 2, Phase 3
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Start of enrollment: 2019 Jul 16
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

25 citations
T-cell target antigens across major gynecologic cancers.
Alba Rodriguez-Garcia, Nicholas G. Minutolo, John M. Robinson, Daniel J. Powell
Gynecologic Oncology. 2017-06-01